Lion Street Advisors LLC Buys 660 Shares of Pfizer Inc. $PFE

Lion Street Advisors LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 6.8% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 10,381 shares of the biopharmaceutical company’s stock after buying an additional 660 shares during the period. Lion Street Advisors LLC’s holdings in Pfizer were worth $252,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer in the first quarter worth $27,000. North Capital Inc. purchased a new stake in Pfizer in the 1st quarter worth $28,000. Bayforest Capital Ltd bought a new stake in Pfizer during the first quarter valued at about $28,000. Horizon Financial Services LLC purchased a new position in shares of Pfizer in the first quarter valued at about $35,000. Finally, WPG Advisers LLC bought a new position in shares of Pfizer in the first quarter worth about $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

PFE opened at $24.72 on Tuesday. The business has a fifty day moving average of $24.88 and a 200 day moving average of $24.12. The stock has a market cap of $140.52 billion, a P/E ratio of 13.15, a PEG ratio of 0.82 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.82.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is currently 91.49%.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent analyst reports. Morgan Stanley decreased their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday. Bank of America boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. UBS Group reaffirmed a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.35.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.